Please assess the completion status of the following clinical trial:

Trial Title: Safety Evaluation of 3K3A-APC in Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Acute ischemic stroke~* Able to receive IV tPA, mechanical thrombectomy or both~* National Institutes of Health Stroke Scale (NIHSS) score of ≥ 5~* Signed informed consent~* Mechanical thrombectomy subjects only: onset time to arterial puncture time \< 6 hours~Exclusion Criteria:~* History of stroke or penetrating head injury within 90 days prior to enrollment~* History of previous or current diagnosis of intracranial hemorrhage that represents a potential for re-hemorrhage if subjected to thrombolytic therapy or mechanical thrombectomy~* Moyamoya disease, cerebral arterio-venous malformation (AVM), known unsecured aneurysm requiring intervention during the acute study period~* Presence of other neurological or non-neurological co-morbidities that may lead, independently of the current stroke, to further deterioration in the subject's neurological status during the trial period~* Presence of premorbid neurological deficits and functional limitations assessed by a retrospective Modified Rankin Scale (mRS) score of ≥ 2~* Mechanical thrombectomy subjects only: baseline non-contrast CT scan revealing a large core occlusion as defined by local protocol~* Prolonged prothrombin time (PT) or activated partial thromboplastin time (aPTT)~* Severe hypertension or hypotension~* Glomerular filtration rate (GFR) \<35 mL/min~* Blood glucose concentration \< 50 mg/dL~* Prior exposure to any exogenous form of APC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 120 µg/kg of 3K3A-APC (Type: ACTIVE_COMPARATOR): 3K3A-APC, q12h for up to 5 doses
- 240 µg/kg of 3K3A-APC (Type: ACTIVE_COMPARATOR): 3K3A-APC, q12h for up to 5 doses
- 360 µg/kg of 3K3A-APC (Type: ACTIVE_COMPARATOR): 3K3A-APC, q12h for up to 5 doses
- 540 µg/kg of 3K3A-APC (Type: ACTIVE_COMPARATOR): 3K3A-APC, q12h for up to 5 doses
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo, q12h for up to 5 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).